227 related articles for article (PubMed ID: 30317534)
1. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
[TBL] [Abstract][Full Text] [Related]
2. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
[TBL] [Abstract][Full Text] [Related]
3. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
4. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
8. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Schmid-Bindert G; Engel-Riedel W; Reck M; Schuette W; Stöhlmacher J; Fischer JR; Mazières J; Chouaid C; Wolf M; Vinolas N; Soldatenkova V; Ripoche V; Nguyen T; Visseren-Grul C
Lung Cancer; 2015 Dec; 90(3):397-404. PubMed ID: 26791798
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Kozloff MF; Martin LP; Krzakowski M; Samuel TA; Rado TA; Arriola E; De Castro Carpeño J; Herbst RS; Tarazi J; Kim S; Rosbrook B; Tortorici M; Olszanski AJ; Cohen RB
Br J Cancer; 2012 Oct; 107(8):1277-85. PubMed ID: 22990652
[TBL] [Abstract][Full Text] [Related]
11. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G
Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641
[TBL] [Abstract][Full Text] [Related]
13. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Okamoto I; Yoshioka H; Takeda K; Satouchi M; Yamamoto N; Seto T; Kasahara K; Miyazaki M; Kitamura R; Ohyama A; Hokoda N; Nakayama H; Yoshihara E; Nakagawa K
J Thorac Oncol; 2012 Feb; 7(2):427-33. PubMed ID: 22071785
[TBL] [Abstract][Full Text] [Related]
16. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Fidias P; Pennell NA; Boral AL; Shapiro GI; Skarin AT; Eder JP; Kwoh TJ; Geary RS; Johnson BE; Lynch TJ; Supko JG
J Thorac Oncol; 2009 Sep; 4(9):1156-62. PubMed ID: 19704336
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
